Table 1.
Patients’ Characteristics And Demographic Data
| Characteristics | No (%) n=105 |
|---|---|
| Age, median (range, yr) | 60 (37–85) |
| Gender | |
| Male | 39 (37.1) |
| Female | 66 (62.9) |
| Primary site | |
| Left lung | 44 (41.9) |
| Right lung | 60 (57.1) |
| Unknown | 1 (1.0) |
| Performance status | |
| ECOG < 2 | 96 (91.4) |
| ECOG ≥ 2 | 9 (8.6) |
| Initial EGFR-TKI | |
| Gefitinib | 60 (57.1) |
| Icotinib | 37 (35.2) |
| Other | 8 (7.6) |
| EGFR mutation status before TKI | |
| Exon 19 deletions | 50 (47.6) |
| Exon 21 L858R | 27 (25.7) |
| Other mutation | 3 (2.9) |
| Unknown | 25(23.8) |
| EGFR mutation status after TKI | |
| Exon 19 deletions | 37 (35.2) |
| Exon 21 L858R | 21 (20.0) |
| No common mutation (Exon 19 deletion and Exon 21 L858R) | 22 (21.0) |
| Unknown | 25 (23.8) |
| PFS of initial TKI, median (range, month) | 17 (1–63) |
| Response of initial TKI | |
| PR | 33 (31.4) |
| SD | 42 (40.0) |
| Unknown | 30 (28.6) |
| Metastasis site | |
| Lung | |
| Yes | 92 (87.6) |
| No | 11 (10.5) |
| Unknown | 2 (1.9) |
| Bone | |
| Yes | 50 (47.6) |
| No | 53 (50.5) |
| Unknown | 2 (1.9) |
| Brain | |
| Yes | 32 (30.5) |
| No | 71 (67.6) |
| Unknown | 2 (1.9) |
| Other | |
| Yes | 19 (18.1) |
| No | 84 (80.0) |
| Unknown | 2 (1.9) |
| Treatment before TKI | |
| Chemotherapy | |
| Yes | 50 (47.6) |
| No | 46 (43.8) |
| Unknown | 9 (8.6) |
| Operation | |
| Yes | 17 (16.2) |
| No | 84 (80.0) |
| Unknown | 4 (3.8) |